Cargando…

The cytokine adsorber Cytosorb® does not reduce ammonia concentrations in critically ill patients with liver failure

Detalles Bibliográficos
Autores principales:	Liebchen, Uwe, Paal, Michael, Gräfe, Caroline, Zoller, Michael, Scharf, Christina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998587/ https://www.ncbi.nlm.nih.gov/pubmed/36763124 http://dx.doi.org/10.1007/s00134-023-06998-w

Ejemplares similares

Can the cytokine adsorber CytoSorb(®) help to mitigate cytokine storm and reduce mortality in critically ill patients? A propensity score matching analysis
por: Scharf, Christina, et al.
Publicado: (2021)

No clinically relevant removal of meropenem by cytokine adsorber CytoSorb(®) in critically ill patients with sepsis or septic shock
por: Liebchen, Uwe, et al.
Publicado: (2021)

Does the cytokine adsorber CytoSorb(®) reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study
por: Scharf, Christina, et al.
Publicado: (2022)

The effect of cytosorb® application on kidney recovery in critically ill patients with severe rhabdomyolysis: a propensity score matching analysis
por: Gräfe, Caroline, et al.
Publicado: (2023)

Blood purification with a cytokine adsorber for the elimination of myoglobin in critically ill patients with severe rhabdomyolysis
por: Scharf, Christina, et al.
Publicado: (2021)

Successful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis: a pilot study
por: Scharf, Christina, et al.
Publicado: (2021)

CytoSorb® Hemoadsorption as a Promising Tool to Handle COVID-19-Induced Cytokine Storm
por: Acevedo, Alice-Christin, et al.
Publicado: (2021)

The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome
por: Scharf, Christina, et al.
Publicado: (2020)

Therapeutic Drug Monitoring of Meropenem and Piperacillin in Critical Illness—Experience and Recommendations from One Year in Routine Clinical Practice
por: Scharf, Christina, et al.
Publicado: (2020)

Systematic Evaluation of Voriconazole Pharmacokinetic Models without Pharmacogenetic Information for Bayesian Forecasting in Critically Ill Patients
por: Kallee, Simon, et al.
Publicado: (2022)

Optimal loading dose of meropenem before continuous infusion in critically ill patients: a simulation study
por: Liebchen, Uwe, et al.
Publicado: (2021)

Evaluation of the MeroRisk Calculator, A User-Friendly Tool to Predict the Risk of Meropenem Target Non-Attainment in Critically Ill Patients
por: Liebchen, Uwe, et al.
Publicado: (2021)

Was ist neu … in der Behandlung von invasiven Mykosen. COVID-19-assoziierte pulmonale Aspergillose
por: Scharf, Christina, et al.
Publicado: (2021)

Extracorporeal adsorption of protective and toxic bile acids and bilirubin in patients with cholestatic liver dysfunction: a prospective study
por: Greimel, Antonia, et al.
Publicado: (2023)

Hemoadsorption in the critically ill—Final results of the International CytoSorb Registry
por: Hawchar, Fatime, et al.
Publicado: (2022)

Pancreatitis cytosorbents (CytoSorb) inflammatory cytokine removal: A Prospective Study (PACIFIC)
por: Huber, Wolfgang, et al.
Publicado: (2019)

The Role of Non-Enzymatic Degradation of Meropenem—Insights from the Bottle to the Body
por: Liebchen, Uwe, et al.
Publicado: (2021)

Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
por: Schatz, Lea Marie, et al.
Publicado: (2023)

Comparison of Cerebrospinal Fluid Collection Through the Proximal and Distal Port Below the Overflow System from an External Ventricular Drain
por: Kinast, Christina Barbara, et al.
Publicado: (2022)

CytoSorb hemoperfusion markedly attenuates circulating cytokine concentrations during systemic inflammation in humans in vivo
por: Jansen, Aron, et al.
Publicado: (2023)

Digestive enzymes of fungal origin as a relevant cause of false positive Aspergillus antigen testing in intensive care unit patients
por: Schroeder, Ines, et al.
Publicado: (2020)

Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC–MS/MS method in human serum
por: Habler, Katharina, et al.
Publicado: (2021)

Piperacillin concentration in relation to therapeutic range in critically ill patients – a prospective observational study
por: Zander, Johannes, et al.
Publicado: (2016)

Therapeutic drug monitoring-guided high dose meropenem therapy of a multidrug resistant Acinetobacter baumannii - A case report
por: Liebchen, U., et al.
Publicado: (2019)

Cytosorb filter: An adjunct for survival in the COVID-19 patient in cytokine storm? a case report
por: Rizvi, Saniya, et al.
Publicado: (2021)

Use of CytoSorb therapy to treat critically ill coronavirus disease 2019 patients: a case series
por: Mehta, Yatin, et al.
Publicado: (2021)

The Use of CytoSorb Therapy in Critically Ill COVID-19 Patients: Review of the Rationale and Current Clinical Experiences
por: Ruiz-Rodríguez, Juan Carlos, et al.
Publicado: (2021)

CytoSorb-friend or foe!!
por: Pattnaik, Saroj Kumar, et al.
Publicado: (2015)

Does adjunctive hemoadsorption with CytoSorb affect survival of COVID-19 patients on ECMO? A critical statement
por: Köhler, Thomas, et al.
Publicado: (2021)

Effective Treatment of Acute Tricyclic Antidepressant Poisoning with Cardiogenic Shock and Severe Rhabdomyolysis Using ECMO and CytoSorb(®) Adsorber
por: Zitoune, Zakaria, et al.
Publicado: (2023)

Cytokine hemoadsorption with CytoSorb® in patients with sepsis: a systematic review and meta-analysis
por: Saldaña-Gastulo, Jiovany Jhan Carlos, et al.
Publicado: (2023)

Reply: Does adjunctive hemoadsorption with CytoSorb® affect survival of COVID-19 patients on ECMO? A critical statement
por: Putzu, Alessandro, et al.
Publicado: (2021)

Extracorporeal hemoadsorption in critically ill COVID-19 patients on VV ECMO: the CytoSorb therapy in COVID-19 (CTC) registry
por: Hayanga, J. W. Awori, et al.
Publicado: (2023)

The Effect of CytoSorb on Inflammatory Markers in Critically Ill Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials*
por: Heymann, Marc, et al.
Publicado: (2023)

Towards model-informed precision dosing of piperacillin: multicenter systematic external evaluation of pharmacokinetic models in critically ill adults with a focus on Bayesian forecasting
por: Greppmair, Sebastian, et al.
Publicado: (2023)

CytoResc – “CytoSorb” Rescue for critically ill patients undergoing the COVID-19 Cytokine Storm: A structured summary of a study protocol for a randomized controlled trial
por: Stockmann, Helena, et al.
Publicado: (2020)

Hemoadsorption with CytoSorb(®) and the early course of linezolid plasma concentration during septic shock
por: Köhler, Thomas, et al.
Publicado: (2021)

Cytokine clearance with CytoSorb® during cardiac surgery: a pilot randomized controlled trial
por: Poli, Elettra C, et al.
Publicado: (2019)

Mortality and adverse events of hemoadsorption with CytoSorb® in critically ill patients: A systematic review and meta‐analysis of randomized controlled trials
por: Heymann, Marc, et al.
Publicado: (2022)

Comment on: Extracorporeal hemoadsorption in critically ill COVID‑19 patients on VV ECMO: the CytoSorb therapy in COVID‑19 (CTC) registry
por: Supady, A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6p6ncbu3lrld6tnneghhnhstsl